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Endothelial function, assessed using brachial artery flow-mediated dilation (FMD), predicts 38 
future cardiovascular disease (CVD) risk. This study established age- and sex-specific 39 
reference intervals for brachial artery FMD in healthy individuals, and examined the relation 40 
with CVD risk factors. In a retrospective study design, we pooled brachial artery FMD 41 
(acquired according to expert-consensus guidelines for FMD protocol and analysis) and 42 
participant characteristics/medical history from 5,362 individuals (4-84 years; 2,076 females). 43 
Healthy individuals (n=1,403 [582 females]) were used to generate age-/sex-specific percentile 44 
curves. Subsequently, we included individuals with CVD risk factors, without overt disease 45 
(un-medicated n=3,167 [1,247 females], and medicated n=792 [247 females]). Multiple linear 46 
regression tested the relation of CVD risk factors (body mass index, blood pressure, 47 
cholesterol, diabetes, dyslipidaemia and smoking) with FMD. Healthy males showed a 48 
negative, curvilinear relation between FMD and age, whilst females revealed a negative linear 49 
relation that started higher, but declined at a faster rate than males. Age- and sex-specific 50 
differences in FMD relate, at least partly, to baseline artery diameter. FMD was related to CVD 51 
risk factors in un-medicated (e.g. systolic-/diastolic blood pressure) and medicated individuals 52 
(e.g. diabetes/dyslipidaemia). Sex mediated some of these effects (P<0.05), with normalisation 53 
of FMD in medicated men, but not women with dyslipidaemia. In conclusion, sex alters the 54 
age-related decline in FMD, which may partly be explained through differences in baseline 55 
diameter. Sex also alters the influence of some CVD risk factors and medication on FMD. This 56 
work improves interpretation and future use of the FMD technique. 57 
 58 
Key words: ageing, sex differences, flow-mediated dilation, reference intervals, risk factors. 59 
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Abbreviations and acronyms 61 
BMI = body mass index 62 
CVD = cardiovascular disease 63 
FMD = flow-mediated dilation 64 
FP = fractional polynomial 65 
HDL = high-density lipoprotein cholesterol 66 
LDL = low-density lipoprotein cholesterol 67 




















1. INTRODUCTION 86 
The vascular endothelium plays a key role in the maintenance of vascular homeostasis (1). 87 
Since endothelial dysfunction contributes to the development and progression of 88 
atherosclerosis, ultimately leading to cardiovascular disease (CVD) (2), studies have explored 89 
strategies to assess endothelial dysfunction as an early biomarker of CVD (3,4). In 1992, 90 
Celermajer et al. introduced the flow-mediated dilation (FMD) approach; a non-invasive 91 
assessment of endothelial function using ultrasonography (5). Brachial artery FMD has now 92 
become a popular research tool, likely due to its non-invasive nature, responsiveness to 93 
interventions (6,7), and correlation with coronary artery endothelial function (4,8,9). Despite 94 
the independent prognostic value of FMD (10-14), even in asymptomatic individuals (10-95 
12,15), some limitations hamper widespread use of the technique. 96 
 97 
Age- and sex-specific differences in FMD have been consistently reported (16-21), with older 98 
age and male sex being associated with lower FMD values. However, marked differences in 99 
FMD values are present between studies, prohibiting meaningful comparisons. Variation 100 
between laboratories in FMD protocol (e.g. timing, occlusion cuff position) and analysis 101 
(manual versus automated) limits between-laboratory comparison. Consistent implementation 102 
of expert-consensus guidelines (14,22) seems a logical solution to these issues, especially since 103 
strict adherence to these guidelines lowers FMD variability (23). Previous work attempted to 104 
construct age- and sex-specific reference values (24). However, this work did not control for 105 
age-related changes in baseline artery diameter and CVD risk factors, i.e. (patho)physiological 106 
indices that importantly contribute to the magnitude and variation of the FMD. This highlights 107 
the need and importance of age- and sex-specific reference values for FMD, collected when 108 




We combined FMD observations from six laboratories that all strictly adhered to protocol 111 
guidelines (14,25) and performed analysis using automated edge-detection and wall-tracking 112 
software. First, using data from 1,403 healthy individuals, we established age- and sex-specific 113 
reference intervals for brachial artery FMD across the entire lifespan. This data also allowed us 114 
to explore the role of age- and sex-specific differences in baseline artery diameter on FMD. 115 
Secondly, we enriched the dataset with 3,959 individuals with established CVD risk factors (i.e. 116 
above international cut-off normative values) and explored how these risk factors, as well as 117 
medication use, impacted the age- and sex-specific FMD reference values.  118 
 119 
2. METHODS 120 
2.1 Study population.  121 
The data that support the findings of this study are available from the corresponding author 122 
upon reasonable request. Research groups from the International Working Group on Flow-123 
Mediated Dilation identified eligible studies that included assessment of brachial artery FMD. 124 
Studies were included if all measurements were performed with adherence to the expert-125 
consensus guidelines on measuring FMD (14,25) and data collection adhered to the Declaration 126 
of Helsinki. All participants provided oral and written informed consent prior to each individual 127 
study. 128 
 129 
We compiled individual-level brachial artery FMD data with corresponding participant 130 
characteristics and medical history from six laboratories (for the list of contributing laboratories 131 
and investigators, see supplementary file; Table S1). With permission from principal 132 
investigators, we also included unpublished data (32% of total observations). When the original 133 
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studies adopted a methodological design with repeated FMD measurements, we included the 134 
FMD that was performed first. 135 
 136 
For our first objective, i.e. age- and sex-specific reference intervals, healthy individuals (4-84 137 
years; 821 males and 582 females) were selected following stringent inclusion criteria (26), 138 
including (when available): (i) systolic blood pressure <140mmHg and diastolic blood pressure 139 
<90mmHg, (ii) body mass index (BMI) <25kg/m2, (iii) waist circumference <102cm for males 140 
and <88cm for females, (iv) total cholesterol <4.9mmol/L, (v) Low-density lipoprotein 141 
cholesterol (LDL) <3mmol/L, (vi) High-density lipoprotein cholesterol (HDL) >1mmol/L for 142 
males and >1.2mmol/L for females, (vii) triglycerides <1.7mmol/L, (viii) glucose <5.6mmol/L, 143 
(ix) never smoked, (x) no history of metabolic- or CVD/event, and (xi) not taking any 144 
medications or hormone-based contraception/therapy. For the second objective, i.e. impact of 145 
CVD risk factors, the remaining participants with one or more risk factor (n=3,959) were 146 
stratified into un-medicated (males; n=545, females; n=247), and medicated individuals 147 
(males; n=1920, females; n=1247). The medicated subpopulation were taking blood pressure-148 
, lipid- and/or glucose-lowering drugs.  149 
 150 
2.2 Flow-mediated dilation: methodological considerations.  151 
We included brachial artery FMD data from research groups strictly adhering to expert-152 
consensus guidelines (14,25). FMD assessments were performed following standardised 153 
participant preparation procedures (i.e. fasted state, abstained from exercise, caffeine and 154 
alcohol, and timing of menstrual cycle) (27). Following 10-15 minutes of supine rest, brachial 155 
artery diameter was assessed via high-resolution duplex ultrasound using a hand-held probe or 156 
probe-holder approach. B-mode images were obtained and optimized, and Doppler velocity 157 
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was recorded simultaneously. After at least 1 minute of baseline diameter and blood flow 158 
velocity measurement, an occlusion cuff, placed distal to the olecranon process, was inflated 159 
to suprasystolic pressure (i.e. >50mmHg above the participant’s systolic blood pressure) for 5 160 
minutes. Recordings were resumed 30 seconds before cuff deflation, and FMD was recorded 161 
for a further 3 minutes post cuff deflation. 162 
  163 
FMD data were analysed using an automated edge-detection and wall-tracking software 164 
(BloodFlow Analysis [n=3,244] or FMD Studio, Quipu SRL [n=2,118]) which is largely 165 
operator independent, and also substantially more reproducible than manual approaches (28). 166 
These software packages track the vessel walls and blood velocity trace in B-mode frames via 167 
a pixel density and frequency distribution algorithm.(28) An optimal region of interest to be 168 
analysed was selected by the sonographer, based on consistent image quality, with a clear 169 
distinction between the artery walls and lumen. Despite the initial region of interest selection 170 
being operator-determined, the remaining analysis was automated and independent of operator 171 
bias (28). Laboratory-specific details of analysis software and ultrasound machines are reported 172 
in the supplementary file (Table S1). 173 
 174 
2.3 Statistical analysis 175 
Statistical analyses were conducted using IBM SPSS version 25 (SPSS Inc., Chicago, IL) 176 
unless stated otherwise.  177 
 178 
We used multiple imputation chained equations to impute missing values (29) for weight, BMI, 179 
systolic-, diastolic- and mean arterial blood pressure, and baseline- and peak diameter (all 180 
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variables had <20% missing data). We generated five imputed datasets, which were used to fit 181 
the relevant regression models and results reported were obtained from the pooled analyses on 182 
all imputed datasets.  183 
For the definition of age- and sex-specific reference intervals for brachial artery FMD, 184 
calculation of age-specific reference intervals were performed in healthy males (n=821) and 185 
females (n=582) separately. Initially, to account for differences in analysis software, we 186 
performed multiple linear regression including a dummy variable for FMD Studio as an 187 
independent determinant of FMD outcome. The regression coefficient for the dummy variable 188 
(β=0.166%) was used as a calibration factor to rescale individual FMD values obtained using 189 
FMD Studio. To calculate age- and sex-specific reference intervals, we utilised fractional 190 
polynomial (FP) regression (30) in STATA software (Stata Corp., College Station, TX, USA) 191 
with the xrigls command. Age-specific 2.5th, 10th, 25th, 50th, 75th, 90th and 97.5th percentile 192 
curves were calculated as meanFMD + Zp x SD, where Zp assumed the values of -1.96, -1.28, 193 
-0.67, 0, 0.67, 1.28, and 1.96, respectively. Age- and sex-specific percentile curves were also 194 
calculated for baseline brachial artery diameter. Furthermore, Pearson correlation coefficient 195 
was used to assess the relationship between baseline diameter and FMD in both the estimated 196 
(derived from the age- and sex-specific percentile curves) and observed (original) outcomes. 197 
Fisher r-to-z transformation was used to compare the correlation coefficient between males and 198 
females. Sensitivity analyses were conducted whereby age- and sex-specific reference intervals 199 
were calculated for males and females ≥9 years and ≥18 years. 200 
 201 
We examined the relation with CVD risk factors. Based on the equations computed for healthy 202 
individuals, we calculated the expected meanFMD and SDFMD for individuals with CVD risk 203 
factors and calculated age- and sex-specific Z-scores as observedFMD - 204 
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expectedFMD/SDexpectedFMD. Z-scores represent the number of SDs above or below the healthy 205 
population mean (50th percentile) of the same age and sex. 206 
 207 
Multiple linear regression determined the relation of CVD risk factors with FMD Z-scores in 208 
four subpopulations (un-medicated and medicated males and females). Age was included in 209 
the regression model to account for any residual effects on outcomes. Sub-analyses were 210 
conducted for smoking and cholesterol, since limited available data were present for these 211 
variables. We added interaction terms between each risk factor and sex to explore whether the 212 
effects of the model predictors are moderated by sex differences. 213 
 214 
3. RESULTS 215 
Participant characteristics are presented for all males and females in Tables 1 and 2, 216 
respectively.  217 
 218 
3.1 Age-/sex-specific reference intervals for brachial artery FMD in the healthy subpopulation.  219 
The best fitting FPs’ powers (p) for meanFMD and SDFMD were both p=1 for females, which 220 
represents a linear relation between FMD and age. For males, the meanFMD p=0 and SDFMD p=-221 
0.5, indicating a curvilinear relation (Figure 1). The equations derived for estimated FMD for 222 
females were: 223 
meanFMD (%) = 9.5947 – 0.0631 x age 224 
SDFMD (%) = 4.5400 – 0.0349 x age 225 
and, for males: 226 
meanFMD (%) = 7.9279 - 1.5725 x ln(age/10) 227 




Given the large difference in available data between sexes in young children, additional FP 230 
regression analyses were performed in individuals ≥9 years and ≥18 years (Supplementary file; 231 
Figures S1 and S2, respectively). These analyses confirmed the primary observations of age- 232 
and sex-dependent variation in FMD. In individuals ≥9 years and ≥18 years we additionally 233 
explored the role of height and found that every 10 cm increase in height is associated with a 234 
0.16 mm (95%CI: 0.14 to 0.18) increase in baseline diameter and a 0.28 % (95%CI: -0.48 to -235 
0.09) decrease in FMD. Importantly, these effects were independent of sex (sex*height 236 
interaction for baseline diameter P=0.481; sex*height interaction %FMD P=0.404). In contrast 237 
our observations in males, we found a negative linear relation between FMD and age in males 238 
≥18 years. Repeating analysis in women and men ≥30 years confirmed the presence of a 239 
negative linear relation between FMD and age in both adult groups (data not shown). Linear 240 
regression was used to explore the effect of scan location (i.e. laboratory) on %FMD, with 241 
laboratories contributing >200 scans being entered in the analysis. With adjustment for basic 242 
demographics (age, sex) and lifestyle (BMI, smoking status) covariates, we found no 243 
statistically significant difference (P≥0.1) for laboratory on %FMD.      244 
 245 
3.2 Age- and sex-specific differences in baseline brachial artery diameter.  246 
The best fitting FPs’ powers (p) for meanBaselineDiameter and SDBaselineDiameter were p=-2 and p=-1 247 
respectively for females, and p=-0.5 and p=-1 respectively for males, indicating a curvilinear 248 
relation in both sexes (Figure 1). 249 
 250 
The equations derived for estimated baseline artery diameter for females were: 251 
meanBaselineDiameter (mm) = 3.3764 – 0.6070 x (age/10)-2 252 
SDBaselineDiameter (mm) = 0.6389 – 0.3195 x (age/10)-1 253 
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and, for males: 254 
meanBaselineDiameter (mm) = 5.8692 – 2.9237 x (age/10)-0.5 255 
SDBaselineDiameter (mm) = 0.7172 - 0.3177 x (age/10)-1 256 
 257 
Corresponding reference intervals (percentiles) derived from the above equations for estimated 258 
FMD and baseline artery diameter are presented in Table 3. 259 
 260 
Correlation analysis demonstrated weak but statistically significant inverse relationships 261 
between observed baseline artery diameter and FMD (female r2=0.163, male r2=0.149; both 262 
P<0.001), which was not different between sex (Fisher’s P=0.697; Figure 2). Additional 263 
analysis between estimated baseline artery diameter and FMD (derived from the equations 264 
above) revealed a strong inverse relation in males (r2=0.975, P<0.001), whilst a significantly 265 
weaker relation was found in females (r2=0.605, P<0.001; Fisher’s P<0.001).  266 
 267 
3.3 Relation of CVD risk factors with FMD percentiles compared to healthy age- and sex-268 
matched individuals. 269 
In the un-medicated subpopulation, lower FMD Z-scores (i.e. lower FMD compared to age-270 
/sex-matched healthy reference values) were found for higher systolic blood pressure in both 271 
males and females (P=0.015 and P<0.001, respectively). Higher diastolic blood pressure was 272 
significantly associated with higher FMD Z-scores in females (P<0.001). Presence of diabetes 273 




In the medicated subpopulation, presence of dyslipidaemia and diabetes were significantly 276 
associated with lower FMD Z-scores in females (both P=0.01). In males, smoking and diabetes 277 
were significantly associated with lower FMD Z-scores (P=0.022 and P=0.027, respectively), 278 
whilst dyslipidaemia was related to higher FMD Z-scores (P=0.029; Table S2). These 279 
observations are largely reinforced when standardised regression coefficients (per SD increase 280 
in- or presence of CVD risk factor) are presented in Figure 3.  281 
 282 
3.4 Sex differences in the relation of CVD risk factors with FMD Z-scores. 283 
Using sex as an interaction term in the regression model revealed that systolic- and diastolic 284 
blood pressure were stronger determinants for FMD in un-medicated females than in males 285 
(both P=0.019, Figure 3). In the medicated subpopulation, no sex differences were found for 286 
systolic and diastolic blood pressure (Figure 3). Whilst presence of dyslipidaemia was not 287 
significantly affected by sex in the un-medicated group, sex altered the effect of dyslipidaemia 288 
on FMD Z-score in the medicated group (Figure 3). More specifically, FMD was supra-289 
normalised in medicated males, whilst FMD in females was lower in those with dyslipidaemia 290 
compared to healthy age- and sex-matched individuals (P<0.001).  291 
 292 
4. DISCUSSION 293 
Following strict adherence to expert-consensus guidelines (14,25), we provide age- and sex-294 
specific reference intervals for brachial artery FMD, where sex altered the age-related decline 295 
in FMD. Healthy males demonstrated a negative curvilinear relation between FMD and age, 296 
whilst females revealed a linear relation, where FMD started higher, but declined at a faster 297 
rate with age compared to males. Importantly, our work revealed that differences in baseline 298 
brachial artery diameter may, at least partly, contribute to the age- and sex-related differences 299 
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in FMD. This suggests that age- and sex-related differences in FMD in healthy individuals 300 
may, in addition to differences in endothelial function, also relate to age- and sex-related 301 
differences in structural characteristics (i.e. baseline diameter). Additionally, our work 302 
provides insight into how CVD risk factors and (cardiovascular-controlling) medications 303 
influence FMD. We found that some CVD risk factors (e.g. blood pressure, diabetes, 304 
dyslipidaemia, BMI) alter age- and sex-related FMD Z-scores, both in un-medicated and 305 
medicated individuals. Moreover, we found that sex altered the impact of CVD risk factors and 306 
medication. Specifically, a larger impact of blood pressure on FMD was evident in un-307 
medicated females compared to males, whilst dyslipidaemia was associated with a lower FMD 308 
in medicated females, but not in males. Taken together, these reference intervals for brachial 309 
artery FMD importantly contribute to improved interpretation of FMD outcomes, but also 310 
extend our knowledge and understanding of factors that influence FMD. 311 
 312 
In the past years, reference values have been estimated for other (pre)clinical tests of vascular 313 
structure (e.g. stiffness (31,32) and intima-media thickness (33) in large arteries, and 314 
media/lumen ratio in small arteries (34)), which contributed to widespread and valid use of the 315 
technique. Importantly, in these examples, efforts were made to standardise assessment prior 316 
to estimating reference intervals. Similarly, we have pooled data from laboratories that strictly 317 
adhere to guidelines for performance and analysis of brachial artery FMD (14,25). The 318 
importance of following these guidelines is supported by our dataset, in that we found no 319 
between-software or between-laboratory differences in FMD results. Importantly, data were 320 
derived from multiple laboratories, different countries, and involved multiple principal 321 
investigators and sonographers. This emphasises that adhering to expert-consensus guidelines 322 
is essential for the future use of FMD, but also highlights the relevance and robustness of the 323 




In the healthy population, and in line with most previous work (16,18-20), we observed an age-326 
related decline in FMD in both sexes. Nonetheless, the rate of change differed between sexes. 327 
Early work reported a linear decline in both groups that starts around the 4th or 5th decade of 328 
life (19). Previous studies, however, are limited by the inclusion of a relatively small age range 329 
and/or have included individuals with CVD risk factors. Another limitation is largely ignoring 330 
the potential role of age- and sex-specific differences in baseline artery diameter, which is 331 
relevant since baseline diameter is inversely related to FMD (35-37). The role of baseline 332 
diameter has extensively discussed in expert-consensus FMD guidelines (14,38), and by 333 
various others (39). Differences in baseline artery diameter may partly contribute the lower 334 
FMD in males compared to females, and may also influence the age-related changes in FMD. 335 
Indeed, the age-related decline in FMD in our data set is mirrored by a concomitant increase in 336 
baseline diameter. This effect seems stronger in males than in females, supported by the 337 
stronger relation between estimated FMD and baseline diameter in males. Furthermore, in 338 
children there was a steeper rate of change in males compared to females, which may contribute 339 
to the characteristic drop in FMD in males (and not in females) during childhood and 340 
adolescence in our data set. This suggests that, in addition to age- and sex-related differences 341 
in endothelial function, also baseline diameter may contribute to age- and sex-related 342 
differences in FMD. However, further work is required, preferably related to a prospective, 343 
within-subject design, to better understand the role of baseline diameter to the age-related 344 
changes in FMD. 345 
 346 
The higher FMD in females, but also the steeper decline in FMD with age, compared to males 347 
may relate to differences in sex hormones, especially since oestrogen has been linked to cardio-348 
protective properties (40). These protective effects of oestrogen may work through 349 
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upregulation of nitric oxide (41), or increasing the sensitivity of the endothelium to increases 350 
in shear stress (27,42). Conversely, in contrast with previous research (19,43), the characteristic 351 
drop in sex hormones associated with menopause did not translate to a steeper decline in FMD 352 
in our study. These discrepancies may be attributed to between-study differences in participant 353 
inclusion criteria (e.g. blood pressure/BMI cut-off values). Our data suggests that remaining 354 
within “normal” ranges for CVD risk factors may be protective against the menopause-related 355 
drop in FMD, although the relatively small sample size of women aged >40 years in our study 356 
must be considered as a potential limitation. However, previous studies are limited by the cross-357 
sectional nature, making it difficult to untangle the impact of menopause versus older age. An 358 
alternative explanation for the gradual decline in FMD with age relates to changes in structural 359 
characteristics of the artery wall, including increases in intima-media thickness (33) and arterial 360 
stiffness (31,32). Also other body characteristics, such as muscle mass or height, may 361 
contribute to our findings. Furthermore, age-related increases in retrograde and oscillatory 362 
shear (44) inflammation, and oxidative stress (45) may also contribute to the gradual age-363 
related decline in FMD in healthy individuals. Future work is required to better understand the 364 
nature and physiological mechanisms underlying this change.  365 
 366 
When examining the relation between CVD risk factors and FMD Z-scores, we found that 367 
blood pressure and diabetes were negatively associated with FMD in un-medicated individuals. 368 
This is not surprising, given previous work related to endothelial dysfunction with the presence 369 
of high blood pressure (46) and diabetes (47), whilst these risk factors also impacted sex- and 370 
age-specific reference values for carotid intima-media thickness (33) and arterial stiffness 371 
(31,32). Moreover, the relation between blood pressure and FMD Z-score disappeared in the 372 
medicated subgroup, implying that FMD is not different from healthy controls when using 373 
drugs that target these risk factors. These findings are supported by previous work in blood 374 
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pressure-lowering medication (48), which found these drugs to (in)directly improve endothelial 375 
function in patients. In contrast to our hypothesis, but also conflicting with previous work (49), 376 
no significant impact on FMD in un-medicated individuals was found in other well-established 377 
risk factors, including BMI, cholesterol and smoking. Our observation does not imply that these 378 
traditional risk factors do not alter endothelial function. A potential explanation for these 379 
findings may relate to the small proportion of available data for smoking and cholesterol 380 
variables. Nonetheless, our data confirms that elevated blood pressure is an important risk 381 
factor associated with endothelial dysfunction. A final consideration relates to the potential role 382 
of structural characteristics, especially since our work supports a role for the diameter 383 
explaining age- and sex-related changes in FMD. Previous work found comparable predictive 384 
values of brachial artery diameter and FMD for CVD events in asymptomatic (50) and 385 
symptomatic populations (51). Additionally, within- or between-subject differences in wall 386 
thickness may also explain differences in FMD, especially since changes in the wall-to-lumen 387 
ratio may alter vascular responsiveness in conduit arteries (52). This warrants further work to 388 
explore the role of structural indices, including the diameter and wall thickness, in changes in 389 
FMD, both with older age and in relation to CVD risk factors. 390 
 391 
We also found that sex affects the impact of CVD risk factors and medication on FMD. In un-392 
medicated individuals, systolic- and diastolic blood pressure were stronger determinants of 393 
FMD Z-score in females than in males. These findings fit with previous observations, in that 394 
untreated hypertensive women showed larger endothelial dysfunction (53) and a stronger 395 
relation between hypertension and myocardial infarction incidence compared to men (54). 396 
However, the larger FMD Z-scores in women with a higher diastolic blood pressure were 397 
unexpected. This observation may relate to the inclusion of unmedicated, healthy individuals 398 
who did not present with hypertension. Interestingly, also unmedicated men showed a trend for 399 
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this positive relation between FMD Z-score and diastolic blood pressure. Interestingly, sex-400 
specific differences for the effect of blood pressure on FMD disappeared in the medicated 401 
group. Additionally, we reported sex differences in the medicated group, with females 402 
demonstrating significantly lower FMD Z-scores than males in the presence of dyslipidaemia. 403 
In fact, FMD Z-scores for medicated males with dyslipidaemia were supra-normalised (i.e. 404 
greater than the healthy population mean of the same age), highlighting the success of drugs 405 
targeting dyslipidaemia in males. Whilst the underlying mechanisms for these sex differences 406 
remain unclear, these observations are extremely important in contemporary medicine where 407 
increased awareness is required that sex differently affects the process of atherosclerosis and 408 
CVD development, as well as the impact of pharmacological treatments.  409 
 410 
Despite the large number of strengths, i.e. large sample size, and all FMD data obtained with 411 
strict protocol guideline adherence, key limitations of this study largely relate to the 412 
retrospective study design. More specifically, data on important factors associated with CVD 413 
risk and vascular function such as physical activity, cardiorespiratory fitness, ethnicity, sex 414 
hormone levels and endothelial markers were not included in the database. These additional 415 
data would have complemented the dataset to gain some mechanistic insight underlying our 416 
major findings.  417 
 418 
5. CONCLUSIONS 419 
In conclusion, we estimated age- and sex-specific percentiles for brachial artery FMD in a 420 
healthy population and explored the relation of CVD risk factors on FMD Z-scores. Notably, 421 
the FMD data included in the present study were obtained with strict adherence to protocol 422 
guidelines (14,25). Despite the large number of studies (and contributing authors) included in 423 
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the analyses, between-study variability was low, emphasising the importance of strict guideline 424 
adherence. More importantly, this also highlights the feasibility and use of FMD for 425 
(pre)clinical work, when guidelines are strictly adhered to. Accordingly, our age- and sex-426 
specific reference values enable better interpretation of FMD outcomes. Moreover, our work 427 
also highlights that sex leads to distinct age-related changes in FMD, but also affects the impact 428 
of some CVD risk factors in (un)medicated individuals.  429 
 430 
6. PERSPECTIVES 431 
Competency in medical knowledge: Sex-specific differences were evident in the age-related 432 
decline in endothelial function, whilst sex also altered the relation between cardiovascular risk 433 
factors and medications versus endothelial function. These data improve our understanding of 434 
endothelial function, highlighting sex-specific differences in the development of 435 
cardiovascular disease and impact of risk factor-targeting medications on endothelial function 436 
in humans. 437 
 438 
Translational outlook: Construction of reference intervals for brachial artery FMD improves 439 
interpretation of FMD data, but also emphasizes the importance of adhering to guidelines in 440 
future FMD studies. This allows for wider uptake of the FMD technique, whilst this may also 441 
facilitate more research to understand the underlying mechanisms of age-, sex- and risk factor-442 
specific differences in endothelial function. 443 
 444 
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Novelty and Significance 610 
What is New? 611 
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 Strong variation between laboratories in performance of the flow-mediated dilation 612 
(FMD) hamper widespread use of this technique, and prohibits meaningful between-613 
laboratory comparison. 614 
 Upon strongly adhering to expert-consensus guidelines for FMD, this study 615 
established age- and sex-specific reference intervals for brachial artery FMD in 616 
healthy individuals, and examined the relation with CVD risk factors.  617 
What is Relevant? 618 
 Men show a negative, curvilinear relation between FMD and age, whilst females 619 
revealed a negative linear relation, which is partly related to baseline diameter.  620 
 Some CVD risk factors, including systolic blood pressure, are related to a lower FMD 621 
in un-medicated individuals.  622 
 The relation between systolic blood pressure and brachial artery FMD disappeared in 623 
medicated individuals. 624 
Summary 625 
 The age-related decline in brachial artery FMD is different between men and women, 626 
which is at least partly explained through differences in baseline diameter.  627 
 CVD risk factors impair brachial artery FMD, with sex altering the influence of some 628 
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8. FIGURE LEGENDS 643 
Figure 1: Age-specific percentiles of brachial artery flow-mediated dilation (FMD; percentage 644 
change from baseline) and baseline diameter (in mm) in males (FMD (A) n=821; 645 
baseline diameter (B) n=790) and females (FMD (C) n=582; baseline diameter (D) 646 
n=571).  647 
 648 
Figure 2: Brachial artery flow-mediated dilation (FMD; percentage change from baseline) and 649 
baseline diameter (in mm) in healthy males (A; n=796) and females (B; n=579). 650 
Pearson correlation coefficient was used to determine the relationship between FMD 651 
and baseline diameter in males and females separately. 652 
 653 
Figure 3: Point estimates and 95% confidence intervals represent the increase in brachial artery 654 
FMD Z-score (in SD from the healthy population mean) per SD increase (or 655 
presence) in risk factor resulting from a multivariable regression model including all 656 
risk factors and age for males (●) and females (○). (A) un-medicated males (n=1920) 657 
and females (n=1247); (B) medicated males (n=545) and females (n=247). BMI – 658 
body mass index; SBP – systolic blood pressure; DBP – diastolic blood pressure; 659 
HDL – high-density lipoprotein cholesterol660 
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Table 1: Participant characteristics of the total male population, and healthy, un-medicated and medicated male subpopulations.  
   CVD risk factors 
Characteristics Total Healthy Un-medicated Medicated 
n 3286 821 1920 545 
Age (years) 42±19 26±15 45±17 58±11 
Body mass index (kg/m2) 26.3±5.2 22.2±3.8 27.2±4.6 29.4±5.0 
Systolic blood pressure (mmHg) 130±17 118±13 133±17 137±16 
Diastolic blood pressure (mmHg) 78±13 70±10 81±12 83±11 
Mean arterial pressure (mmHg) 95±14 86±10 98±14 101±13 
Total cholesterol [mmol/L (n)] 5.1±1.0 (1756) 4.2±0.5 (105) 5.3±1.0 (1252) 4.9±1.1 (399) 
LDL cholesterol [mmol/L (n)] 3.2±0.9 (1562) 2.3±0.5 (87) 3.4±0.9 (1139) 3.0±1.0 (336) 
HDL cholesterol [mmol/L (n)] 1.2±0.4 (1613) 1.4±0.2 (89) 1.2±0.4 (1181) 1.2±0.4 (343) 
Total-to-HDL cholesterol ratio (n) 4.4±1.3 (1612) 3.0±0.5 (89) 4.5±1.3 (1180) 4.3±1.3 (343) 
Triglycerides [mmol/L (n)] 1.6±1.1 (1670) 0.9±0.4 (92) 1.6±1.1 (1221) 1.7±1.1 (357) 
Plasma glucose [mmol/L (n)] 5.5±1.5 (1293) 4.7±0.6 (83) 5.3±1.1 (982) 6.6±2.4 (228) 
Baseline artery diameter (mm) 4.37±0.86 3.90±0.83 4.46±0.82 4.75±0.72 
FMD (%) 5.56±2.91 6.66±3.24 5.45±2.72 4.30±2.42 
Current smoker [n (%)] 127 (3.9) 0 102 (5.3) 25 (4.6) 
Diabetes [n (%)] 288 (8.8) 0 107 (5.6) 181 (33.2) 
Dyslipidaemia [n (%)] 1474 (44.9) 0 1074 (55.9) 400 (73.4) 
Blood pressure-lowering medication [n (%)] 499 (15.2) 0 0 499 (91.6) 
Lipid-lowering medication [n (%)] 253 (7.7) 0 0 253 (46.4) 
Glucose-lowering medication [n (%)] 167 (5.1) 0 0 167 (30.6) 
Data are presented as mean±SD. For blood metabolites, n represents the number of available data within the respective subpopulation. For 
categorical data, data are presented as n (percentage of subpopulation). HDL – high-density lipoprotein cholesterol; LDL – low-density lipoprotein 
cholesterol; FMD – flow-mediated dilation. 
30 
 
Table 2: Participant characteristics of the total female population, and healthy, un-medicated and medicated female subpopulations.  
   CVD risk factors 
Characteristics Total Healthy Un-medicated Medicated 
n 2076 582 1247 247 
Age (years) 41±18 28±16 44±16 56±12 
Body mass index (kg/m2) 25.7±6.3 21.6±3.5 26.9±6.1 29.5±7.1 
Systolic blood pressure (mmHg) 125±19 113±12 129±18 138±18 
Diastolic blood pressure (mmHg) 76±12 68±10 78±12 81±14 
Mean arterial pressure (mmHg) 92±15 83±10 94±14 98±17 
Total cholesterol [mmol/L (n)] 5.3±1.0 (1150) 4.3±0.4 (119) 5.1±1.0 (839) 5.3±1.0 (192) 
LDL cholesterol [mmol/L (n)] 3.3±0.9 (999) 2.3±0.4 (93) 3.4±0.8 (737) 3.2±1.0 (169) 
HDL cholesterol [mmol/L (n)] 1.5±0.4 (1026) 1.7±0.3 (99) 1.5±0.4 (755) 1.6±0.4 (172) 
Total-to-HDL cholesterol ratio (n) 3.6±1.0 (1025) 2.6±0.4 (98) 3.8±1.0 (755) 3.6±1.0 (172) 
Triglycerides [mmol/L (n)] 1.2±0.9 (1066) 0.8±0.3 (100) 1.2±0.8 (783) 1.5±1.3 (183) 
Plasma glucose [mmol/L (n)] 5.0±0.9 (866) 4.6±0.5 (107) 5.0±0.7 (656) 5.8±1.6 (103) 
Baseline artery diameter (mm) 3.51±0.66 3.25±0.61 3.58±0.64 3.78±0.66 
FMD (%) 6.62±3.47 7.78±3.77 6.36±3.22 5.18±3.13 
Current smoker [n (%)] 97 (4.7) 0 78 (6.3) 19 (7.7) 
Diabetes [n (%)] 119 (5.7) 0 37 (3.0) 82 (33.2) 
Dyslipidaemia [n (%)] 883 (42.5) 0 708 (56.8) 175 (70.9) 
Blood pressure-lowering medication [n (%)] 216 (10.4) 0 0 216 (87.4) 
Lipid-lowering medication [n (%)] 73 (3.5) 0 0 73 (29.6) 
Glucose-lowering medication [n (%)] 81 (3.9) 0 0 81 (32.8) 
Data are presented as mean±SD. For blood metabolites, n represents the number of available data within the respective subpopulation. For 
categorical data, data are presented as n (percentage of subpopulation). HDL – high-density lipoprotein cholesterol; LDL – low-density lipoprotein 
cholesterol; FMD – flow-mediated dilation.
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Table 3: Age- and sex-specific percentiles of brachial artery FMD (%) and baseline artery diameter (mm) in healthy females and males, derived 
from the predictive equations. 




2.5th 10th 25th 50th 75th 90th 97.5th  2.5th 10th 25th 50th 75th 90th 97.5th 
FMD (%) 5 0.72 3.69 6.35 9.28 12.20 14.87 17.84  -0.15 3.03 5.89 9.02 12.15 15.00 18.18 
 10 0.75 3.60 6.16 8.96 11.77 14.33 17.18  0.64 3.17 5.44 7.93 10.42 12.69 15.21 
 15 0.78 3.51 5.96 8.65 11.34 13.79 16.52  0.84 3.08 5.08 7.29 9.50 11.50 13.74 
 20 0.80 3.41 5.76 8.33 10.91 13.25 15.86  0.88 2.95 4.80 6.83 8.87 10.72 12.79 
 25 0.83 3.32 5.56 8.02 10.47 12.71 15.21  0.87 2.82 4.57 6.49 8.41 10.16 12.10 
 30 0.86 3.23 5.36 7.70 10.04 12.17 14.55  0.83 2.70 4.37 6.20 8.03 9.71 11.57 
 35 0.88 3.14 5.16 7.39 9.61 11.63 13.89  0.79 2.58 4.19 5.96 7.73 9.34 11.13 
 40 0.91 3.05 4.96 7.07 9.18 11.10 13.23  0.73 2.47 4.03 5.74 7.46 9.02 10.76 
 45 0.93 2.95 4.77 6.76 8.74 10.56 12.58  0.68 2.37 3.89 5.56 7.23 8.75 10.45 
 50 0.96 2.86 4.57 6.44 8.31 10.02 11.92  0.62 2.28 3.76 5.40 7.03 8.52 10.17 
 55 0.99 2.77 4.37 6.12 7.88 9.48 11.26  0.57 2.19 3.65 5.24 6.85 8.3 9.93 
 60 1.01 2.68 4.17 5.81 7.45 8.94 10.60  0.51 2.11 3.54 5.11 6.68 8.11 9.71 
 65 1.04 2.59 3.97 5.49 7.02 8.40 9.95  0.46 2.03 3.44 4.98 6.53 7.94 9.51 
 70 1.07 2.49 3.78 5.18 6.58 7.86 9.29  0.41 1.95 3.34 4.87 6.39 7.78 9.33 
 75 1.09 2.40 3.57 4.86 6.15 7.32 8.63  0.36 1.88 3.25 4.76 6.26 7.64 9.16 
 80 1.12 2.31 3.38 4.55 5.72 6.78 7.97  0.31 1.82 3.17 4.66 6.15 7.50 9.01 
Baseline artery 10 2.14 2.36 2.56 2.77 2.98 3.18 3.40  2.16 2.43 2.68 2.95 3.21 3.46 3.73 
diameter (mm) 15 2.27 2.56 2.82 3.11 3.39 3.65 3.94  2.49 2.84 3.14 3.48 3.82 4.13 4.47 
 20 2.29 2.61 2.90 3.22 3.55 3.84 4.16  2.71 3.09 3.43 3.80 4.18 4.52 4.90 
 25 2.28 2.63 2.94 3.28 3.62 3.93 4.28  2.86 3.26 3.62 4.02 4.42 4.78 5.18 
 30 2.27 2.63 2.95 3.31 3.67 3.99 4.35  2.98 3.40 3.77 4.18 4.59 4.96 5.38 
 35 2.25 2.63 2.96 3.33 3.69 4.03 4.40  3.08 3.50 3.89 4.31 4.73 5.11 5.53 
 40 2.24 2.62 2.96 3.34 3.71 4.05 4.43  3.16 3.59 3.98 4.41 4.83 5.22 5.66 
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 45 2.23 2.62 2.97 3.35 3.73 4.07 4.46  3.22 3.66 4.06 4.49 4.92 5.32 5.76 
 50 2.23 2.62 2.97 3.35 3.74 4.09 4.48  3.28 3.72 4.12 4.56 5.00 5.40 5.84 
 55 2.22 2.61 2.97 3.36 3.75 4.10 4.49  3.33 3.78 4.18 4.62 5.06 5.47 5.92 
 60 2.21 2.60 2.97 3.36 3.75 4.11 4.51  3.37 3.83 4.23 4.68 5.12 5.53 5.98 
 65 2.21 2.60 2.97 3.36 3.76 4.12 4.52  3.41 3.87 4.27 4.72 5.17 5.58 6.03 
 70 2.20 2.60 2.97 3.36 3.76 4.12 4.53  3.45 3.90 4.31 4.76 5.21 5.62 6.08 
 75 2.20 2.60 2.97 3.37 3.77 4.13 4.53  3.48 3.94 4.35 4.80 5.25 5.67 6.12 
 80 2.19 2.60 2.97 3.37 3.77 4.13 4.54  3.51 3.97 4.38 4.84 5.29 5.70 6.16 
FMD – flow-mediated dilation
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